BIO-TECHNE Corp Revenue from Contract with Customer, Excluding Assessed Tax
BIO-TECHNE Corp (TECH) reported Revenue from Contract with Customer, Excluding Assessed Tax of $1.22 billion for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-24
- BIO-TECHNE Corp revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $321.19M, a 1.33% increase year-over-year.
- BIO-TECHNE Corp revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $311.42M, a 1.51% decline year-over-year.
- BIO-TECHNE Corp revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $295.88M, a 0.39% decline year-over-year.
- BIO-TECHNE Corp revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $286.56M, a 1.00% decline year-over-year.
- BIO-TECHNE Corp revenue from contract with customer, excluding assessed tax for fiscal 2026 was $1.22B, a 0.38% decline from fiscal 2025.
- BIO-TECHNE Corp revenue from contract with customer, excluding assessed tax for fiscal 2025 was $1.22B, a 5.23% increase from fiscal 2024.
- BIO-TECHNE Corp revenue from contract with customer, excluding assessed tax for fiscal 2024 was $1.16B, a 1.97% increase from fiscal 2023.
- BIO-TECHNE Corp revenue from contract with customer, excluding assessed tax for fiscal 2023 was $1.14B, a 2.81% increase from fiscal 2022.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $321.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-24 | $632.61M derived: sum of 2 quarters · filed 2026-08-24 | $928.48M derived: sum of 3 quarters · filed 2026-08-24 | $1.22B 10-K · filed 2026-08-24 |
| 2026-03-31 | $311.42M 10-Q · filed 2026-05-06 | $607.29M derived: sum of 2 quarters · filed 2026-05-06 | $893.85M 10-Q · filed 2026-05-06 | $1.21B derived: sum of 4 quarters · filed 2026-08-24 |
| 2025-12-31 | $295.88M 10-Q · filed 2026-02-04 | $582.43M 10-Q · filed 2026-02-04 | $899.40M derived: sum of 3 quarters · filed 2026-08-24 | $1.22B derived: sum of 4 quarters · filed 2026-08-24 |
| 2025-09-30 | $286.56M 10-Q · filed 2025-11-05 | $603.52M derived: sum of 2 quarters · filed 2026-08-24 | $919.70M derived: sum of 3 quarters · filed 2026-08-24 | $1.22B derived: sum of 4 quarters · filed 2026-08-24 |
| 2025-06-30 | $316.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-24 | $633.14M derived: sum of 2 quarters · filed 2026-08-24 | $930.18M derived: sum of 3 quarters · filed 2026-08-24 | $1.22B 10-K · filed 2026-08-24 |
| 2025-03-31 | $316.18M 10-Q · filed 2026-05-06 | $613.21M derived: sum of 2 quarters · filed 2026-05-06 | $902.67M 10-Q · filed 2026-05-06 | $1.21B derived: sum of 4 quarters · filed 2026-08-24 |
| 2024-12-31 | $297.03M 10-Q · filed 2026-02-04 | $586.49M 10-Q · filed 2026-02-04 | $892.59M derived: sum of 3 quarters · filed 2026-08-24 | $1.20B derived: sum of 4 quarters · filed 2026-08-24 |
| 2024-09-30 | $289.46M 10-Q · filed 2025-11-05 | $595.56M derived: sum of 2 quarters · filed 2026-08-24 | $898.99M derived: sum of 3 quarters · filed 2026-08-24 | $1.17B derived: sum of 4 quarters · filed 2026-08-24 |
| 2024-06-30 | $306.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-24 | $609.53M derived: sum of 2 quarters · filed 2026-08-24 | $882.13M derived: sum of 3 quarters · filed 2026-08-24 | $1.16B 10-K · filed 2026-08-24 |
| 2024-03-31 | $303.43M 10-Q · filed 2025-05-08 | $576.03M derived: sum of 2 quarters · filed 2025-05-08 | $852.96M 10-Q · filed 2025-05-08 | $1.15B derived: sum of 4 quarters · filed 2025-08-22 |
| 2023-12-31 | $272.60M 10-Q · filed 2025-02-06 | $549.53M 10-Q · filed 2025-02-06 | $850.85M derived: sum of 3 quarters · filed 2025-08-22 | $1.14B derived: sum of 4 quarters · filed 2025-08-22 |
| 2023-09-30 | $276.94M 10-Q · filed 2024-11-05 | $578.25M derived: sum of 2 quarters · filed 2025-08-22 | $872.40M derived: sum of 3 quarters · filed 2025-08-22 | $1.14B derived: sum of 4 quarters · filed 2025-08-22 |
| 2023-06-30 | $301.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-22 | $595.47M derived: sum of 2 quarters · filed 2025-08-22 | $867.05M derived: sum of 3 quarters · filed 2025-08-22 | $1.14B 10-K · filed 2025-08-22 |
| 2023-03-31 | $294.15M 10-Q · filed 2024-05-06 | $565.73M derived: sum of 2 quarters · filed 2024-05-06 | $835.38M 10-Q · filed 2024-05-06 | $1.12B derived: sum of 4 quarters · filed 2024-08-22 |
| 2022-12-31 | $271.58M 10-Q · filed 2024-02-07 | $541.24M 10-Q · filed 2024-02-07 | $829.46M derived: sum of 3 quarters · filed 2024-08-22 | $1.12B derived: sum of 4 quarters · filed 2024-08-22 |
| 2022-09-30 | $269.65M 10-Q · filed 2023-11-07 | $557.88M derived: sum of 2 quarters · filed 2024-08-22 | $848.26M derived: sum of 3 quarters · filed 2024-08-22 | $1.12B derived: sum of 4 quarters · filed 2024-08-22 |
| 2022-06-30 | $288.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-22 | $578.60M derived: sum of 2 quarters · filed 2024-08-22 | $847.88M derived: sum of 3 quarters · filed 2024-08-22 | $1.11B 10-K · filed 2024-08-22 |
| 2022-03-31 | $290.38M 10-Q · filed 2023-05-08 | $559.65M derived: sum of 2 quarters · filed 2023-05-08 | $817.37M 10-Q · filed 2023-05-08 | $1.08B derived: sum of 4 quarters · filed 2023-08-23 |
| 2021-12-31 | $269.28M 10-Q · filed 2023-02-07 | $527.00M 10-Q · filed 2023-02-07 | $786.02M derived: sum of 3 quarters · filed 2023-08-23 | $1.03B derived: sum of 4 quarters · filed 2023-08-23 |
| 2021-09-30 | $257.72M 10-Q · filed 2022-11-07 | $516.75M derived: sum of 2 quarters · filed 2023-08-23 | $760.30M derived: sum of 3 quarters · filed 2023-08-23 | $984.55M derived: sum of 4 quarters · filed 2023-08-23 |
| 2021-06-30 | $259.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-23 | $502.58M derived: sum of 2 quarters · filed 2023-08-23 | $726.83M derived: sum of 3 quarters · filed 2023-08-23 | $931.03M 10-K · filed 2023-08-23 |
| 2021-03-31 | $243.55M 10-Q · filed 2022-05-09 | $467.81M derived: sum of 2 quarters · filed 2022-05-09 | $672.00M 10-Q · filed 2022-05-09 | $847.84M derived: sum of 4 quarters · filed 2022-08-24 |
| 2020-12-31 | $224.25M 10-Q · filed 2022-02-07 | $428.45M 10-Q · filed 2022-02-07 | $604.29M derived: sum of 3 quarters · filed 2022-08-24 | $798.97M derived: sum of 4 quarters · filed 2022-08-24 |
| 2020-09-30 | $204.20M 10-Q · filed 2021-11-08 | $380.03M derived: sum of 2 quarters · filed 2022-08-24 | $574.71M derived: sum of 3 quarters · filed 2022-08-24 | $759.65M derived: sum of 4 quarters · filed 2022-08-24 |
| 2020-06-30 | $175.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-08-24 | $370.51M derived: sum of 2 quarters · filed 2022-08-24 | $555.45M derived: sum of 3 quarters · filed 2022-08-24 | $738.69M 10-K · filed 2022-08-24 |
| 2020-03-31 | $194.68M 10-Q · filed 2021-05-07 | $379.61M derived: sum of 2 quarters · filed 2021-05-07 | $562.86M 10-Q · filed 2021-05-07 | $754.52M derived: sum of 4 quarters · filed 2021-08-25 |
| 2019-12-31 | $184.93M 10-Q · filed 2021-02-08 | $368.18M 10-Q · filed 2021-02-08 | $559.84M derived: sum of 3 quarters · filed 2021-08-25 | $744.70M derived: sum of 4 quarters · filed 2021-08-25 |
| 2019-09-30 | $183.24M 10-Q · filed 2020-11-09 | $374.91M derived: sum of 2 quarters · filed 2021-08-25 | $559.77M derived: sum of 3 quarters · filed 2021-08-25 | $734.28M derived: sum of 4 quarters · filed 2021-08-25 |
| 2019-06-30 | $191.66M derived: 10-K 12 month − 10-Q 9 month · filed 2021-08-25 | $376.53M derived: sum of 2 quarters · filed 2021-08-25 | $551.04M derived: sum of 3 quarters · filed 2021-08-25 | $714.01M 10-K · filed 2021-08-25 |
| 2019-03-31 | $184.86M 10-Q · filed 2020-05-11 | $359.37M derived: sum of 2 quarters · filed 2020-05-11 | $522.34M 10-Q · filed 2020-05-11 | $702.60M derived: sum of 4 quarters · filed 2020-08-26 |
| 2018-12-31 | $174.51M 10-Q · filed 2020-02-06 | $337.48M 10-Q · filed 2020-02-06 | $517.73M derived: sum of 3 quarters · filed 2020-08-26 | $681.71M derived: sum of 4 quarters · filed 2020-08-26 |
| 2018-09-30 | $162.97M 10-Q · filed 2019-11-06 | $343.22M derived: sum of 2 quarters · filed 2020-08-26 | $507.20M derived: sum of 3 quarters · filed 2020-08-26 | $661.35M derived: sum of 4 quarters · filed 2020-08-26 |
| 2018-06-30 | $180.25M derived: 10-K 12 month − 10-Q 9 month · filed 2020-08-26 | $344.23M derived: sum of 2 quarters · filed 2020-08-26 | $498.38M derived: sum of 3 quarters · filed 2020-08-26 | $642.99M 10-K · filed 2020-08-26 |
| 2018-03-31 | $163.97M 10-Q · filed 2019-05-07 | $318.13M derived: sum of 2 quarters · filed 2019-05-07 | $462.74M 10-Q · filed 2019-05-07 | |
| 2017-12-31 | $154.15M 10-Q · filed 2019-02-07 | $298.77M 10-Q · filed 2019-02-07 | ||
| 2017-09-30 | $144.61M 10-Q · filed 2018-11-07 | |||
| 2017-06-30 | $563.00M 10-K/A · filed 2019-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |